Montelukast induces beneficial behavioral outcomes and reduces inflammation in male and female rats
BackgroundAccumulative data links inflammation and immune dysregulation to the pathophysiology of mental disorders; little is known regarding leukotrienes’ (LTs) involvement in this process. Circumstantial evidence suggests that treatment with leukotriene modifying agents (LTMAs) such as montelukast...
Main Authors: | Ira S. Rostevanov, Batya Betesh-Abay, Ahmad Nassar, Elina Rubin, Sarit Uzzan, Jacob Kaplanski, Linoy Biton, Abed N. Azab |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.981440/full |
Similar Items
-
Chronic Treatment with <i>Nigella sativa</i> Oil Exerts Antimanic Properties and Reduces Brain Inflammation in Rats
by: Sarit Uzzan, et al.
Published: (2024-02-01) -
The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic
by: Ludwig Aigner, et al.
Published: (2020-12-01) -
Anti-TNF-α Compounds as a Treatment for Depression
by: Sarit Uzzan, et al.
Published: (2021-04-01) -
Pediatric Asthma: Where Has Montelukast Gone?
by: Marco Maglione, et al.
Published: (2023-03-01) -
Montelukast and Coronavirus Disease 2019: A Scoping Review
by: Niusha Sharifinejad, et al.
Published: (2021-08-01)